187 related articles for article (PubMed ID: 22761317)
1. A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength.
Baud'huin M; Solban N; Cornwall-Brady M; Sako D; Kawamoto Y; Liharska K; Lath D; Bouxsein ML; Underwood KW; Ucran J; Kumar R; Pobre E; Grinberg A; Seehra J; Canalis E; Pearsall RS; Croucher PI
Proc Natl Acad Sci U S A; 2012 Jul; 109(30):12207-12. PubMed ID: 22761317
[TBL] [Abstract][Full Text] [Related]
2. A soluble bone morphogenetic protein type 1A receptor fusion protein treatment prevents glucocorticoid-Induced bone loss in mice.
Geng Q; Heng K; Li J; Wang S; Sun H; Sha L; Guo Y; Nie X; Wang Q; Dai L; Zhu X; Kang J; Shao L; Zhai J; Miao S; Lin Q; Guo K; Wang J
Am J Transl Res; 2019; 11(7):4232-4247. PubMed ID: 31396331
[TBL] [Abstract][Full Text] [Related]
3. Treatment With a Soluble Bone Morphogenetic Protein Type 1A Receptor (BMPR1A) Fusion Protein Increases Bone Mass and Bone Formation in Mice Subjected to Hindlimb Unloading.
Ko FC; Van Vliet M; Ellman R; Grasso D; Brooks DJ; Spatz JM; Conlon C; Aguirre JI; Wronski TJ; Bouxsein ML
JBMR Plus; 2017 Oct; 1(2):66-72. PubMed ID: 30283882
[TBL] [Abstract][Full Text] [Related]
4. Targeted disruption of BMP signaling through type IA receptor (BMPR1A) in osteocyte suppresses SOST and RANKL, leading to dramatic increase in bone mass, bone mineral density and mechanical strength.
Kamiya N; Shuxian L; Yamaguchi R; Phipps M; Aruwajoye O; Adapala NS; Yuan H; Kim HK; Feng JQ
Bone; 2016 Oct; 91():53-63. PubMed ID: 27402532
[TBL] [Abstract][Full Text] [Related]
5. Controversy of physiological vs. pharmacological effects of BMP signaling: Constitutive activation of BMP type IA receptor-dependent signaling in osteoblast lineage enhances bone formation and resorption, not affecting net bone mass.
Kamiya N; Atsawasuwan P; Joiner DM; Waldorff EI; Goldstein S; Yamauchi M; Mishina Y
Bone; 2020 Sep; 138():115513. PubMed ID: 32603910
[TBL] [Abstract][Full Text] [Related]
6. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway.
Kamiya N; Ye L; Kobayashi T; Mochida Y; Yamauchi M; Kronenberg HM; Feng JQ; Mishina Y
Development; 2008 Nov; 135(22):3801-11. PubMed ID: 18927151
[TBL] [Abstract][Full Text] [Related]
7. Osteoblast-Specific Overexpression of Human WNT16 Increases Both Cortical and Trabecular Bone Mass and Structure in Mice.
Alam I; Alkhouli M; Gerard-O'Riley RL; Wright WB; Acton D; Gray AK; Patel B; Reilly AM; Lim KE; Robling AG; Econs MJ
Endocrinology; 2016 Feb; 157(2):722-36. PubMed ID: 26584014
[TBL] [Abstract][Full Text] [Related]
8. Treatment with soluble bone morphogenetic protein type 1A receptor fusion protein alleviates irradiation-induced bone loss in mice through increased bone formation and reduced bone resorption.
Wang S; Li J; Sun H; Sha L; Guo Y; Gu G; Mao J; Nie X; Zhai Y; Yu D; Zhai J; Li H; Shan X; Dai C; Wu X; He X; Xin L; Liu J; Heng K; Geng Q
Am J Transl Res; 2020; 12(3):743-757. PubMed ID: 32269709
[TBL] [Abstract][Full Text] [Related]
9. Thrombin receptor deficiency leads to a high bone mass phenotype by decreasing the RANKL/OPG ratio.
Tudpor K; van der Eerden BC; Jongwattanapisan P; Roelofs JJ; van Leeuwen JP; Bindels RJ; Hoenderop JG
Bone; 2015 Mar; 72():14-22. PubMed ID: 25460576
[TBL] [Abstract][Full Text] [Related]
10. Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone.
Harada S; Mizoguchi T; Kobayashi Y; Nakamichi Y; Takeda S; Sakai S; Takahashi F; Saito H; Yasuda H; Udagawa N; Suda T; Takahashi N
J Bone Miner Res; 2012 Feb; 27(2):461-73. PubMed ID: 22052469
[TBL] [Abstract][Full Text] [Related]
11. Disruption of BMP signaling in osteoblasts through type IA receptor (BMPRIA) increases bone mass.
Kamiya N; Ye L; Kobayashi T; Lucas DJ; Mochida Y; Yamauchi M; Kronenberg HM; Feng JQ; Mishina Y
J Bone Miner Res; 2008 Dec; 23(12):2007-17. PubMed ID: 18684091
[TBL] [Abstract][Full Text] [Related]
12. Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development.
Okamoto M; Murai J; Yoshikawa H; Tsumaki N
J Bone Miner Res; 2006 Jul; 21(7):1022-33. PubMed ID: 16813523
[TBL] [Abstract][Full Text] [Related]
13. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic avenues in bone repair: Harnessing an anabolic osteopeptide, PEPITEM, to boost bone growth and prevent bone loss.
Lewis JW; Frost K; Neag G; Wahid M; Finlay M; Northall EH; Abudu O; Davis ET; Powell E; Palmer C; Lu J; Rainger GE; Iqbal AJ; Chimen M; Mahmood A; Jones SW; Edwards JR; Naylor AJ; McGettrick HM
Cell Rep Med; 2024 May; 5(5):101574. PubMed ID: 38776873
[TBL] [Abstract][Full Text] [Related]
15. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
Kostenuik PJ; Nguyen HQ; McCabe J; Warmington KS; Kurahara C; Sun N; Chen C; Li L; Cattley RC; Van G; Scully S; Elliott R; Grisanti M; Morony S; Tan HL; Asuncion F; Li X; Ominsky MS; Stolina M; Dwyer D; Dougall WC; Hawkins N; Boyle WJ; Simonet WS; Sullivan JK
J Bone Miner Res; 2009 Feb; 24(2):182-95. PubMed ID: 19016581
[TBL] [Abstract][Full Text] [Related]
16. Osteoblastic γ-aminobutyric acid, type B receptors negatively regulate osteoblastogenesis toward disturbance of osteoclastogenesis mediated by receptor activator of nuclear factor κB ligand in mouse bone.
Takahata Y; Takarada T; Hinoi E; Nakamura Y; Fujita H; Yoneda Y
J Biol Chem; 2011 Sep; 286(38):32906-17. PubMed ID: 21828041
[TBL] [Abstract][Full Text] [Related]
17. Sclerostin vaccination mitigates estrogen deficiency induction of bone mass loss and microstructure deterioration.
Wang FS; Wu RW; Lain WS; Tsai TC; Chen YS; Sun YC; Ke HJ; Li JC; Hwang J; Ko JY
Bone; 2018 Jul; 112():24-34. PubMed ID: 29653294
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of Bone Morphogenetic Proteins Type 1a Receptor (BMPR1a) in Breast Cancer Cells Protects Bone from Breast Cancer-Induced Osteolysis by Suppressing RANKL Expression.
Liu Y; Zhang RX; Yuan W; Chen HQ; Tian DD; Li H; Jiang X; Deng ZL; Wang Y
Cell Physiol Biochem; 2018; 45(5):1759-1771. PubMed ID: 29495003
[TBL] [Abstract][Full Text] [Related]
19. Elevated Gα11 expression in osteoblast lineage cells promotes osteoclastogenesis and leads to enhanced trabecular bone accrual in response to pamidronate.
Dela Cruz A; Grynpas MD; Mitchell J
Am J Physiol Endocrinol Metab; 2016 May; 310(10):E811-20. PubMed ID: 27006198
[TBL] [Abstract][Full Text] [Related]
20. Dual Role of Cyanidin-3-glucoside on the Differentiation of Bone Cells.
Park KH; Gu DR; So HS; Kim KJ; Lee SH
J Dent Res; 2015 Dec; 94(12):1676-83. PubMed ID: 26350961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
